Coagulation Factor V is a T cell inhibitor expressed by leukocytes in COVID-19
iScience
; 2022.
Article
in English
| EuropePMC | ID: covidwho-1695175
ABSTRACT
Clotting Factor V (FV) is primarily synthesised in the liver and when cleaved by thrombin forms pro-coagulant Factor Va (FVa). Using whole blood RNAseq and scRNAseq of peripheral blood mononuclear cells we find that FV mRNA is expressed in leukocytes, and identify neutrophils, monocytes and T regulatory cells as sources of increased FV in hospitalised patients with COVID-19. Proteomic analysis confirms increased FV in circulating neutrophils in severe COVID-19, and immunofluorescence microscopy identifies FV in lung-infiltrating leukocytes in COVID-19 lung disease. Increased leukocyte FV expression in severe disease correlates with T cell lymphopenia. Both plasma-derived and a cleavage resistant recombinant FV, but not thrombin cleaved FVa, suppress T cell proliferation in vitro. Anticoagulants that reduce FV conversion to FVa, including heparin, may have the unintended consequence of suppressing the adaptive immune system. Graphical
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Language:
English
Journal:
IScience
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS